Bpc 157 vs Tb 500
Which Is Right for You? Complete Comparison (2026)
BPC-157 vs TB-500 — two of the most popular healing peptides compared. BPC-157 excels at gut, tendon.
Bpc 157 vs Tb 500: At a Glance
Bpc 157
- ✓Stable gastric pentadecapeptide from human gastric juice protein
- ✓Promotes angiogenesis and blood vessel formation at injury sites
- ✓Accelerates tendon, ligament, muscle, and bone healing in animal studies
- ✓Protects and heals GI mucosa — counteracts NSAID damage
- ✓No human clinical trials to date (extensive animal data)
Tb 500
- ✓Synthetic fragment of thymosin beta-4 (43-amino acid protein)
- ✓Promotes cell migration and tissue repair
- ✓Anti-inflammatory — reduces inflammatory cytokines
- ✓Stimulates blood vessel growth at injury sites
- ✓Systemic effect — does not need local injection near injury
Detailed Comparison
| Feature | Bpc 157 | Tb 500 |
|---|---|---|
| Mechanism | Gastric pentadecapeptide | Thymosin beta-4 synthetic fragment |
| Dosing | 250-500 mcg SC 1-2x daily (near injury site) | 2-2.5 mg SC 2x/week (loading), then 2x/month (maintenance) |
| Administration | Subcutaneous injection or oral | Subcutaneous injection |
| Half-life | Stable in gastric juice; plasma half-life not well-characterized | Not well-characterized — systemic distribution |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — research peptide |
| Key Trial | Sikiric P et al. J Physiol Paris 1999 — pharmacological review | Goldstein AL et al. Expert Opin Biol Ther 2012 — comprehensive review |
| Side Effects | Generally well-tolerated in studies; injection site discomfort | Injection site irritation, headache, lethargy; generally well-tolerated |
Which Should You Choose?
BPC-157 (Body Protection Compound) (gastric pentadecapeptide) and TB-500 (Thymosin Beta-4 fragment) (thymosin beta-4 synthetic fragment) serve different clinical roles despite both being in the Healing peptide space. BPC-157 (Body Protection Compound) stable gastric pentadecapeptide derived from human gastric juice. TB-500 (Thymosin Beta-4 fragment) synthetic fragment of thymosin beta-4 that promotes tissue repair, reduces inflammation, and stimulates cell migration and blood vessel growth.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Track Both in Shotlee
Shotlee supports tracking any medication or peptide. Compare your results across different protocols with clean dose logs and outcome data.
Making an Informed Choice Between Bpc 157 and Tb 500
Choosing between Bpc 157 and Tb 500 depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Bpc 157 and Tb 500 is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Bpc 157 vs Tb 500: Common Questions
Yes. Many users run both peptides simultaneously because they have complementary mechanisms — BPC-157 targets local tissue via nitric oxide and growth factor pathways, while TB-500 works systemically via actin regulation. Combined protocols are common in injury recovery.
BPC-157 has more direct research on tendon-to-bone healing and is generally preferred for localized tendon and ligament injuries. TB-500 may be added for more systemic or widespread musculoskeletal issues.
BPC-157 is the clear choice for gut issues. It was originally isolated from gastric juice and has extensive research on gut lining repair, IBD-like conditions, and NSAID-induced damage. TB-500 does not have specific gut healing research.
BPC-157 is commonly dosed at 250–500mcg 1–2x daily via subcutaneous injection near the injury site. TB-500 is typically loaded at 2–5mg 2x/week for 4–6 weeks, then reduced to a maintenance dose of 2mg weekly. Both are also available orally, though injectable forms are more common.
Both peptides have relatively mild side effect profiles in user reports. BPC-157 may cause nausea or dizziness at higher doses. TB-500 can cause temporary head rushes or lethargy. Neither is FDA-approved, so long-term safety data in humans is limited.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
References
- [1]ReviewSikiric P et al. The pharmacological properties of the novel peptide BPC 157 (PL-10). J Physiol Paris. 1999;93(6):501-510.
- [2]ReviewSeiwerth S et al. BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lesson from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989.
- [3]ReviewGoldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51.
Track Bpc 157 or Tb 500 in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
🚀 Use Shotlee for Free